Myopathy clinical trials at UCSD

• A Study of the Efficacy and Safety of 24 Week Treatment With REN001 in Patients With Primary Mitochondrial Myopathy

  open to eligible people ages 18 years and up

  This is a randomized, double-blind, placebo-controlled, parallel group, multi-centre, study designed to investigate the efficacy and safety of REN001 administered once daily over a 24-week period to patients with PMM.

  La Jolla, California and other locations

Last updated: October 13, 2021